Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Classical hematology 1

Conditions

Neoplasms 1Myelodysplastic Syndromes 1Leukemia 1Anemia, Refractory 1

Interventions

Epoetin Alfa 25Darbepoetin alfa 17apixaban 9Rivaroxaban 9Dalteparin 7Heparin, Low-Molecular-Weight 6Surveys and Questionnaires 5Meropenem 5fludarabine phosphate 4Vancomycin 4Tinzaparin 4Enoxaparin 4Cyclosporine 4Cefepime 4ferric carboxymaltose 3edoxaban 3Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Ceftazidime 3Carboplatin 3Busulfan 3Antilymphocyte Serum 3Amikacin 3romiplostim 2peginesatide 2hematide 2fludarabine 2epoetin beta 2bemiparin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Abatacept × Classical hematology × Clear all
NCT01012492 2019-11-21

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

Boston Children's Hospital

Phase 2 Completed
11 enrolled 10 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Leukemia, Myelodysplastic Syndromes, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡